FAMPRIDINE TEVA LP 10 mg, extended-release tablet 28 tablets
Active ingredients: Dalfampridine
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FAMPRIDINE TEVA LP 10 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium PVC PVDC de 28 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 15 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Jul 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67942073CIP73023486CIP133400930234860Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FAMPRIDINEcomprimé | 10 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.